BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36223449)

  • 1. Minimally invasive, sustained-release relaxin-2 microparticles reverse arthrofibrosis.
    Kirsch JR; Williamson AK; Yeritsyan D; Blessing WA; Momenzadeh K; Leach TR; Williamson PM; Korunes-Miller JT; DeAngelis JP; Zurakowski D; Nazarian RM; Rodriguez EK; Nazarian A; Grinstaff MW
    Sci Transl Med; 2022 Oct; 14(666):eabo3357. PubMed ID: 36223449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
    Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
    Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges.
    Qiu S; Fu X; Shi Y; Zang H; Zhao Y; Qin Z; Lin G; Zhao X
    Mol Pharm; 2023 Aug; 20(8):3947-3959. PubMed ID: 37358639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis.
    Blessing WA; Okajima SM; Cubria MB; Villa-Camacho JC; Perez-Viloria M; Williamson PM; Sabogal AN; Suarez S; Ang LH; White S; Flynn E; Rodriguez EK; Grinstaff MW; Nazarian A
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12183-12192. PubMed ID: 31160441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.
    Parikh A; Patel D; McTiernan CF; Xiang W; Haney J; Yang L; Lin B; Kaplan AD; Bett GC; Rasmusson RL; Shroff SG; Schwartzman D; Salama G
    Circ Res; 2013 Jul; 113(3):313-21. PubMed ID: 23748429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.
    D'Ercole A; Nistri S; Pacini L; Carotenuto A; Santoro F; Papini AM; Bathgate RAD; Bani D; Rovero P
    Front Pharmacol; 2022; 13():942178. PubMed ID: 36034864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin in hepatic fibrosis: What is known and where to head?
    Ezhilarasan D
    Biochimie; 2021 Aug; 187():144-151. PubMed ID: 34102254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats.
    Kim JK; Lee JI; Paik YH; Yun CO; Chang HY; Lee SY; Lee KS
    J Gene Med; 2016; 18(1-3):16-26. PubMed ID: 26769058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
    Sassoli C; Nistri S; Chellini F; Bani D
    Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure.
    Zheng G; Cai J; Chen X; Chen L; Ge W; Zhou X; Zhou H
    Biol Pharm Bull; 2017; 40(7):960-966. PubMed ID: 28674260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.
    Illiano S; Poirier B; Minoletti C; Pasquier O; Riva L; Chenede X; Menguy I; Guillotel M; Prigent P; Le Claire S; Gillot F; Thill G; Lo Presti F; Corbier A; Le Bail JC; Grailhe P; Monteagudo E; Ingenito R; Bianchi E; Philippo C; Duclos O; Mallart S; Bathgate R; Janiak P
    Sci Rep; 2022 Nov; 12(1):20435. PubMed ID: 36443381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
    Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
    Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors.
    Tapia Cáceres F; Gaspari TA; Hossain MA; Samuel CS
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin Attenuates Organ Fibrosis
    Barsha G; Walton SL; Kwok E; Mirabito Colafella KM; Pinar AA; Hilliard Krause LM; Gaspari TA; Widdop RE; Samuel CS; Denton KM
    Kidney360; 2021 Nov; 2(11):1781-1792. PubMed ID: 35373008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.
    Beiert T; Knappe V; Tiyerili V; Stöckigt F; Effelsberg V; Linhart M; Steinmetz M; Klein S; Schierwagen R; Trebicka J; Roell W; Nickenig G; Schrickel JW; Andrié RP
    Int J Cardiol; 2018 Jan; 250():21-28. PubMed ID: 29169754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
    Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
    Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
    Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
    Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
    Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of dexamethasone and RU 486, an antigestagen and antiglucocorticoid, on progesterone and relaxin secretion in hysterectomized pigs with aging corpora lutea.
    Li Y; Huang CJ; Cho SJ; Anderson LL
    Anim Reprod Sci; 1998 Apr; 51(2):131-41. PubMed ID: 9672675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.